Who was studied, and how
Three numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 2 other studies
people with obesity, in this paper
The trial randomly assignedassigned by chance
both agents (semaglutide and tirzepatide)
placebo
Probably increased overall GI adverse events1.9×
randomisedThe trial randomly assignedassigned by chance
tirzepatide
placebo
Probably increased overall GI adverse events2.9×
randomisedthe abstract, start to end
Overall GI adverse events were 1.86 times higher with *both* agents (95% CI=1.56, 2.21), with tirzepatide showing a greater risk (RR 2.94, 95% CI=2.61, 3.32) than semaglutide (RR 1.68, 95% CI=1.46, 1.94).
← favours treatmentfavours comparator →
could be chanceOverall GI adverse eventsboth agents (semaglutide and tirzepatide) vs placebo
RR 1.861.56–2.21
Overall GI adverse eventstirzepatide vs placebo
RR 2.942.61–3.32
Overall GI adverse eventssemaglutide vs placebo
RR 1.681.46–1.94
GLP-1 receptor agonistsGIP/GLP-1 & amylin agonistsAdverse events & safety
GIP/GLP-1 & amylin agonists × adverse events & safetyharms?mixed
unlikelylikely
0.00not counted
GLP-1 receptor agonists × adverse events & safetyharms?mixed
unlikelylikely
0.02not counted
← favours treatmentfavours comparator →
1 / 6